Home LiteratureArticle Details
PMID: 22822606 Published · ppublish fin

[Update on current care guidelines: ovarian cancer].

Duodecim; laaketieteellinen aikakauskirja ·Vol. 128 ·No. 12 ·2012-09-20

Leminen Arto, Auranen Annika, Bützow Ralf, Hietanen Sakari, Komulainen Marja, Kuoppala Tapio, Mäenpää Johanna, Puistola Ulla, Vuento Maarit, Vuorela Piia, Yliskoski Merja

Abstract

Ovarian cancer is the most lethal gynaecological cancer. It appears that seemingly ovarian or primary peritoneal carcinomas, in fact, originate from fimbriae. BRCA1/2 mutation carriers are recommended for the removal of ovaries and fimbriae, to reduce the risk of cancer. Treatment of epithelial ovarian cancer is based on the combination of surgery and chemotherapy. The residual tumour volume at the primary operation is the most important predictive factor of survival. The best response at the primary treatment is observed with combination chemotherapy with taxane and platinum. Adding bevacitzumab to first line chemotherapy may improve survival.

Article Info
Journal
Duodecim; laaketieteellinen aikakauskirja
Abbr.
Duodecim
ISSN
0012-7183
Published
2012-09-20
Indexed
2012-07-24
Updated
2015-11-19
Language
fin
Country/Region
Finland
NLM ID
0373207
External Links
PubMed source
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com